SAN FRANCISCO – All those involved in the biopharma industry are always worried about something – it's in our nature. Even when the times are good we tend to fret about whether they will last. Well, bring out the anxiety pills: The 2016 U.S. presidential election is just around the corner, bringing with it a host of uncertainties about the pricing of medicines, which has reverberated into lower biotech valuations in the stock market.